Your “Quarterly Quality Meeting” Is About to Become an Inspection Finding
Many management reviews still look like old-QSR checkboxes. Under QMSR, FDA is looking for documented decisions, action tracking, and evidence of active oversight.
Management review used to be a relatively quiet part of the quality system.
The meeting happened. Slides were presented. Trend charts appeared.
Minutes got approved.
Under the old QSR framework, FDA often focused primarily on whether management review occurred at all.
Under QMSR, that changes significantly.
Because once FDA aligned more closely with ISO 13485, management review stopped being just a required event and became something more consequential:
Evidence of whether executive leadership is actively managing the quality system.
That distinction matters more than many companies realize.
Inspectors can now evaluate the entire management review record—not just attendance or minutes, but:
required inputs
documented decisions
resource commitments
action items
and whether actions actually closed the loop
Which means the informal “quarterly quality update meeting” many organizations still run today can quickly become an inspection issue.
And the pattern is remarkably consistent.
The meeting happens - complaints, CAPAs, audits, supplier issues, maybe a few trend charts.
Everyone nods. Minutes get written.
But when FDA reviews the record, the questions start:
Where are the required ISO 13485 inputs?
Where are the decisions tied to QMS effectiveness?
Where did management allocate resources?
Where was follow-through verified?
Without those elements, the record stops demonstrating oversight and starts demonstrating lack of oversight, and that’s where the real risk sits.
Because FDA is increasingly treating management review as evidence of executive control over the QMS—not simply quality department activity.
And once inspectors begin connecting management review records to CAPAs, complaint trends, supplier issues, and recurring quality problems, those records stop looking administrative and become evidence.
The companies handling this transition well are reframing management review entirely. Not as a compliance meeting, but as a structured, evidence-based executive process with defined inputs, documented decisions, action tracking, and verification.
Because under QMSR, FDA is no longer simply asking whether leadership reviewed the quality system.
They’re asking whether leadership actually managed it.
